Copley Scientific Showcases Extensive Range of Tablet Testing Equipment at Analytica 2014
Copley Scientific will focus on systems from the company’s comprehensive range of test equipment for pharmaceutical solid dosage forms at Analytica 2014, which takes place from 1– 4 April 2014 in Munich, Germany. On show will be the Dissolution Tester DIS 8000, a rugged unit with eight stirred test vessels that is ideal for both R&D and routine QC applications. Like all Copley Scientific tablet dissolution testers it meets the latest specifications of the US, European and other pharmacopoeias.
With automation an increasing requirement, Copley Scientific’s Dissofract ‘Off-Line’ Dissolution Sampling System will be shown with the DIS 8000. The Dissofract is specifically designed to automatically remove samples from either six or eight dissolution vessels at predetermined times and deposit them in test tubes or HPLC vials for subsequent analysis. Dissofract delivers minimal cross contamination, short sampling times and supports the efficient and accurate assessment of dissolution profiles.
Copley Scientific is also a world-leading manufacturer of inhaler test equipment. Visitors to the stand at Analytica will be able to learn more about the market leading Next Generation Impactor (NGI) together with Abbreviated Impactor Measurement (AIM) inhaled testing tools, including the Fast Screening Impactor (FSI), and the Fast Screening Andersen (FSA).
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.